Vinylbital

Vinylbital

Vinylbital is a barbiturate derivative developed in the 1930s. It has sedative and hypnotic properties, and was used for the induction of anesthesia and for the treatment of insomnia, but has largely been superseded by newer drugs with improved safety profiles.

History

Vinylbital was first synthesized in the 1930s as part of a series of barbiturate derivatives developed by Bayer. It was marketed under the trade name Alurate for use as a sedative and hypnotic.

Pharmacology

As a barbiturate, vinylbital acts as a GABA_A receptor agonist. It enhances the action of the neurotransmitter GABA at the GABA_A receptor, leading to increased inhibition of the central nervous system. This results in sedation, hypnosis, and a decrease in anxiety.

Medical uses

Vinylbital was used for the induction of anesthesia and for the treatment of insomnia. However, it has largely been replaced by newer drugs such as benzodiazepines and nonbenzodiazepines, which have a better safety profile and fewer side effects.

Side effects

Side effects of vinylbital can include drowsiness, confusion, and dependency. Overdose can lead to respiratory depression and death.

Legal status

In many countries, including the United States, vinylbital is a controlled substance due to its potential for abuse and dependency.

See also

• Barbiturate
• GABA_A receptor
• Benzodiazepine
• Nonbenzodiazepine

‎